Immunotherapy for infectious diseases in haematological immunocompromise.

Maria-Teresa Cutino-Moguel, Chris Eades, Katayoun Rezvani, Darius Armstrong-James

Journal: British journal of haematology 2017;177(3):348-356

PMID: 28369798

Abstract

Opportunistic infections remain a major problem across a broad spectrum of immunocompromised haematological patient groups, with viruses, bacteria, fungi and protozoa all presenting significant challenges. Given the major difficulties in treating many of these infections with the currently available antimicrobial chemotherapeutic arsenal, and the rapid emergence of antimicrobial resistance amongst all of the microbial kingdoms, novel strategies that enable host control or elimination of infection are urgently required. Recently, major progress has been made in our understanding of host immunocompromise in the haematological patient. In addition, a wide range of novel immunomodulatory strategies for infectious diseases have been developed. Here we discuss the major and wide-ranging areas of progress that have been made for host-directed immunotherapies in the context of infectious diseases, with relevance to haematological immunocompromise.

© 2017 John Wiley & Sons Ltd.

Address: Department of Virology, Kings College Hospital, London, UK.; Department of Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK.; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.; Fungal Pathogens Laboratory, National Heart and Lung Institute, Imperial College London, London, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.